DC-SIGN expression on myeloid population in Luminal Breast Cancer

Open data API in a single place

Provided by Zenodo

Get early access to DC-SIGN expression on myeloid population in Luminal Breast Cancer API!

Let us know and we will figure it out for you.

Dataset information

Country of origin
Updated
2020.01.21 00:00
Created
2019.06.19
Available languages
English
Keywords
Quality scoring

Dataset description

DC-SIGN expression by the different populations of DC and macrophages found in breast tumor samples using flow cytometry. As previously described (doi:10.1038/s41590-018-0145-8.), we identified four major DC populations: CD11c − CD123+ plasmacytoid pre-DCs, CD11c+BDCA1+ CD14− DCs, CD11c+ BDCA1− CD14− DCs, and CD11c+ BDCA1+ CD14+ inflammatory DCs. Staining was performed using the following antibodies: anti-CD45 APC-Cy7 (BD), anti-CD14 Qdot 605 (Thermo), anti-CD3 Alexa700 (Biolegend), anti-CD 19 Alexa700 (Biolegend), anti-CD56 Alexa700 (Biolegend), 400 anti-HLA-DR BV711 (Biolegend), anti-CD11c PC5 (Beckman Coulter), anti-BDCA-1 PE (BD), anti-CD123 PCy7 (BD) and anti-C-SIGN FITC (BD). Cells were analyzed by a LSRFORTESSA X-20 instrument (BD Biosciences). The most prominent intratumoral myeloid cell population, however, was shown to be represented by macrophages, defined as CD11c+ BDCA1−CD14+ cells. We analyzed DC-SIGN expression on the surface of these populations by flow cytometry. DC-SIGN was only expressed on the membrane of macrophages from tumoral as well as juxtatumoral tissues, but not on the DC populations analyzed. These results are represented in Figure 4 from the publication "Aberrant fucosylation enables breast cancer clusterin to interact with dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN)".   
European data infrastructure with broad catalog discovery, free evaluation access and production-grade API options.
190K+
indexed dataset pages
32
countries and EU institutions
2019
API-first since
Free API quota
for evaluation and prototypes
SLA
history and push on production APIs
FAQ

Questions before production use

Practical answers on evaluation, licensing, freshness, versioning and support.

api.store is built and operated by Apitalks s.r.o. Company details and a direct contact path are linked in the footer for vendor checks and procurement review.
Yes. Selected APIs include a free API quota, so your team can validate coverage, freshness, response shape and workflow fit before asking for a production plan.
Often yes, but usage rights depend on the source license and dataset. We surface source, license and update metadata where available, and can help review terms before a production integration.
Maintained APIs include update metadata where available. For production integrations, we can add history, monitoring and push updates so changes are easier to detect and act on.
Production APIs can add SLA, stable identifiers, versioning support, history, push updates and direct support around the data your product or AI workflow depends on.

Didn't find the API you need?

Let us know and we will figure it out for you.

European data discovery with free evaluation access and production-grade API options.

Copyright © 2026. Made by Apitalks